News | Cardiovascular Surgery | July 26, 2019

Keck School of Medicine Promotes Patient Diversity in Cardiac Surgery Clinical Trials

$4.5 million National Institutes of Health grant supports efforts to evaluate new surgical approaches to treat cardiovascular disease and recruit patients typically underrepresented in clinical trials

Keck School of Medicine Promotes Patient Diversity in Cardiac Surgery Clinical Trials

July 26, 2019 — A highly competitive $4.5 million grant from the National Institutes of Health (NIH) National Heart, Lung and Blood Institute (NHLBI) will support Keck School of Medicine of USC efforts to recruit patients from underrepresented populations into cardiac surgery clinical trials. The seven-year grant funds the Keck School’s ongoing research contributions to the Cardiothoracic Surgical Trials Network (CTSN), the formal NIH infrastructure for conducting major clinical trials in cardiac surgery. The grant also establishes an implementation science training program to address the critical need to develop methods to translate clinical research findings into clinical practice.

Clinical trials provide researchers with insight into how people are likely to respond to medical interventions, including surgery. Factors such as age, weight, genetics, ethnic origin and geographic location all play a role in how a person may react to different treatments. For that reason, representation of diverse patient populations in clinical trials enables researchers to better address public health concerns.

“Nearly half of Los Angeles residents are Hispanic, making the Keck School uniquely positioned to recruit a large, underrepresented population in cardiac surgery trials,” said principal investigator Michael Bowdish, M.D., MS, associate professor of surgery and preventive medicine at the Keck School. “By increasing patient diversity in cardiac surgery clinical trials, we are better suited to address cardiovascular disease, the No. 1 cause of mortality in the United States.”

The Keck School, through relationships with the Los Angeles County Department of Health Services, will recruit potential patients from areas with a large Hispanic presence, according to Bowdish. Potential patients also will be identified through the Southern California Clinical and Translational Science Institute (SC CTSI), which provides outreach and education to more than 30 predominantly Hispanic community health organizations in Los Angeles.

“Addressing the cardiovascular needs of our community is top priority,” said Vaughn A. Starnes, M.D., chair and distinguished professor of surgery and H. Russell Smith Foundation Chair for Stem Cell and Cardiovascular Thoracic Research at the Keck School. “This prestigious award provides us with valuable resources to discover novel and innovative therapies to improve the health of our Los Angeles community and beyond.”

The Keck School will collaborate with Saint Luke's Mid America Heart Institute in Kansas City, Missouri, as Linked Clinical Research Centers. This expands the patient pool for gathering and assessing data, enabling researchers to achieve stronger and more definitive research results, according to Bowdish.

In addition, the implementation science training program, under the leadership of Cecilia Patino-Sutton, M.D., Ph.D., MEd, associate professor of preventive medicine at the Keck School, will explore novel ways to translate findings from clinical research in cardiac surgery into clinical practice. The program also will leverage collaborative relationships between the Keck School, SC CTSI, the USC Gehr Family Center for Health Systems Science, and the USC Leonard D. Schaeffer Center for Health Policy and Economics, as well as the Mid America Heart Institute Cardiovascular Research Fellowship.

Keck Medicine of USC has been an active member of the CTSN since 2010. The CTSN includes more than 40 major academic medical centers across the United States and Canada, and more than 20 hospitals in Europe.

For more information: www.keck.usc.edu

Related Content

FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
Overlay Init